CDKN2A and melanoma: Identified high-penetrance variants for melanoma risk include cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase 4 (CDK4), an alternate reading frame (ARF) of CDKN2A, and a locus on 1p22 [7,8].